Mega%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520cv

## Mega%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520cv ### Overview Mega%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520cv is a broad-spectrum antimicrobial agent. ### Primary Indications * Complicated urinary tract infections (cUTIs) * Intra-abdominal infections (cIAIs) * Pneumonia (community-acquired and hospital-acquired) ### Adult Dosing * **cUTIs and cIAIs:** 1.5 grams IV every 8 hours. * **Pneumonia:** 1.5 grams IV every 8 hours. * Maximum daily dose is generally 4.5 grams. Specific dosing may vary based on local protocols and organism susceptibility. ### Pediatric Dosing Dosing in pediatric patients is not well-established and should be determined by a specialist. ### Dose Adjustments * **Renal Impairment:** Dose reduction is necessary for patients with impaired renal function. For creatinine clearance (CrCl) < 50 mL/min, adjust dose based on CrCl. Consult product labeling for specific recommendations. * **Hepatic Impairment:** No dose adjustment is typically required. ### Contraindications * Known hypersensitivity to Mega%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520cv or other beta-lactam antimicrobials. ### Adverse Effects Common adverse effects include nausea, vomiting, diarrhea, rash, and headache. Serious adverse effects may include C. difficile-associated diarrhea, hypersensitivity reactions, and neurotoxicity. ### Key Drug Interactions * **Probenecid:** May increase serum concentrations of Mega%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520cv. * **Valproic acid:** May decrease serum concentrations of valproic acid. ### Monitoring * Monitor for signs and symptoms of hypersensitivity reactions. * Monitor for effectiveness of treatment (e.g., resolution of fever, decrease in white blood cell count). * Monitor renal function, especially in patients with pre-existing renal impairment or those receiving concurrent nephrotoxic agents. ### Clinical Pearls * Mega%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520cv should be used in combination with other antimicrobial agents for certain polymicrobial infections. * Resistance can develop; susceptibility testing is recommended. *** *Disclaimer: This information is intended for clinical pharmacists and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making treatment decisions. Dosing and recommendations may vary based on individual patient factors and local protocols.*